• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Acute ocriplasmin retinopathy.急性玻璃酸酶性视网膜病变
Retina. 2015 Jun;35(6):1055-8. doi: 10.1097/IAE.0000000000000667.
2
Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe art thou?奥克纤溶酶的安全性与并发症：奥克纤溶酶，奥克纤溶酶；噢，你究竟有多安全？
JAMA Ophthalmol. 2014 Apr 1;132(4):379-80. doi: 10.1001/jamaophthalmol.2014.278.
3
Understanding the adverse effects of ocriplasmin.了解奥克纤溶酶的不良反应。
JAMA Ophthalmol. 2015 Feb;133(2):229. doi: 10.1001/jamaophthalmol.2014.4484.
4
Understanding the adverse effects of ocriplasmin - reply.了解奥克纤溶酶的不良反应——回复
JAMA Ophthalmol. 2015 Feb;133(2):230. doi: 10.1001/jamaophthalmol.2014.4505.
5
Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction.奥克纤溶酶用于有症状的玻璃体黄斑粘连/牵引的药物治疗的安全性概况。
Retina. 2015 Jun;35(6):1111-27. doi: 10.1097/IAE.0000000000000448.
6
SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.用于有症状性玻璃体黄斑粘连的奥克裂纤酶的安全性概况：上市前和上市后经验的综合分析
Retina. 2015 Jun;35(6):1128-34. doi: 10.1097/IAE.0000000000000519.
7
Early panretinal abnormalities on fundus autofluorescence and spectral domain optical coherence tomography after intravitreal ocriplasmin.玻璃体内注射奥克纤溶酶后眼底自发荧光和光谱域光学相干断层扫描早期全视网膜异常。
Acta Ophthalmol. 2016 Mar;94(2):e160-2. doi: 10.1111/aos.12749. Epub 2015 May 24.
8
Transient vision loss after ocriplasmin injection.注射奥克纤溶酶后的短暂视力丧失。
Retina. 2015 Jun;35(6):1107-10. doi: 10.1097/IAE.0000000000000542.
9
Ocriplasmin: nonsurgical option for VMA and macular hole, but with potential barriers to practical use.奥克纤溶酶：玻璃体黄斑粘连和黄斑裂孔的非手术治疗选择，但在实际应用中存在潜在障碍。
Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr;44(2):113-6; discussion p.113. doi: 10.3928/23258160-20130313-02.
10
Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection.玻璃体内注射欧立珠单抗后急性全视网膜结构和功能异常。
JAMA Ophthalmol. 2014 Apr 1;132(4):484-6. doi: 10.1001/jamaophthalmol.2013.8142.

引用本文的文献

1
Method for Quantitative Analysis of Vitreoretinal Adhesion in Ex Vivo Model.定量分析离体模型中玻璃体视网膜粘连的方法。
Transl Vis Sci Technol. 2024 Oct 1;13(10):3. doi: 10.1167/tvst.13.10.3.
2
Enzymatic vitreolysis using reengineered derived collagenase.利用工程化衍生胶原酶进行酶玻璃体溶解术。
Mol Vis. 2021 Apr 1;27:125-141. eCollection 2021.
3
The internal limiting membrane: Roles in retinal development and implications for emerging ocular therapies.内界膜：在视网膜发育中的作用及其对新兴眼部治疗方法的影响。
Exp Eye Res. 2021 May;206:108545. doi: 10.1016/j.exer.2021.108545. Epub 2021 Mar 20.
4
A review of treatment for retinopathy of prematurity.早产儿视网膜病变的治疗综述。
Expert Rev Ophthalmol. 2019;14(2):73-87. doi: 10.1080/17469899.2019.1596026. Epub 2019 Mar 29.
5
Reduced perfusion density of superficial retinal capillary plexus after intravitreal ocriplasmin injection for idiopathic vitreomacular traction.玻璃体内注射奥克纤溶酶治疗特发性玻璃体黄斑牵引后视网膜浅表毛细血管丛灌注密度降低
BMC Ophthalmol. 2019 May 10;19(1):108. doi: 10.1186/s12886-019-1119-9.
6
EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy.全视野视网膜电图降低的评估：OASIS 试验 ERG 子研究结果。
Retina. 2018 Feb;38(2):364-378. doi: 10.1097/IAE.0000000000001536.
7
[Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].与经结膜玻璃体切除术相比，使用奥克纤溶酶进行药理玻璃体溶解术作为有症状的局灶性玻璃体黄斑牵引伴或不伴黄斑裂孔（≤400μm）的一种治疗选择
Ophthalmologe. 2017 Feb;114(2):148-154. doi: 10.1007/s00347-016-0322-9.
8
Rhegmatogenous retinal detachment following intravitreal ocriplasmin.玻璃体内注射奥克纤溶酶后孔源性视网膜脱离
Graefes Arch Clin Exp Ophthalmol. 2016 Dec;254(12):2333-2338. doi: 10.1007/s00417-016-3398-7. Epub 2016 Jun 8.
9
Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.玻璃体内注射奥克纤溶酶治疗玻璃体黄斑牵引和黄斑裂孔：玻璃体脱离预测因素及潜在并发症的荟萃分析与综合综述
Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1247-56. doi: 10.1007/s00417-016-3363-5. Epub 2016 Apr 30.
10
Ocriplasmin: who is the best candidate?奥克纤溶酶：最佳适用人群是谁？
Clin Ophthalmol. 2016 Mar 17;10:485-95. doi: 10.2147/OPTH.S97947. eCollection 2016.

本文引用的文献

1
Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.玻璃体内注射奥克纤溶酶治疗玻璃体黄斑牵拉和黄斑裂孔后，光谱域光学相干断层扫描（SD-OCT）显示的视网膜外层反射率变化
Retina. 2015 Jun;35(6):1144-50. doi: 10.1097/IAE.0000000000000544.
2
Transient vision loss after ocriplasmin injection.注射奥克纤溶酶后的短暂视力丧失。
Retina. 2015 Jun;35(6):1107-10. doi: 10.1097/IAE.0000000000000542.
3
Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction.奥克纤溶酶用于有症状的玻璃体黄斑粘连/牵引的药物治疗的安全性概况。
Retina. 2015 Jun;35(6):1111-27. doi: 10.1097/IAE.0000000000000448.
4
SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.用于有症状性玻璃体黄斑粘连的奥克裂纤酶的安全性概况：上市前和上市后经验的综合分析
Retina. 2015 Jun;35(6):1128-34. doi: 10.1097/IAE.0000000000000519.
5
Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection.与玻璃体内注射奥克纤溶酶相关的严重急性视力丧失、色觉障碍以及频域光学相干断层扫描上椭圆体带的变化。
Retin Cases Brief Rep. 2015 Spring;9(2):145-8. doi: 10.1097/ICB.0000000000000120.
6
Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?奥克纤溶酶是否会影响黄斑裂孔中视网膜色素上皮细胞与光感受器的黏附？
Br J Ophthalmol. 2015 May;99(5):635-8. doi: 10.1136/bjophthalmol-2014-305620. Epub 2014 Nov 17.
7
Understanding the adverse effects of ocriplasmin.了解奥克纤溶酶的不良反应。
JAMA Ophthalmol. 2015 Feb;133(2):229. doi: 10.1001/jamaophthalmol.2014.4484.
8
Understanding the adverse effects of ocriplasmin - reply.了解奥克纤溶酶的不良反应——回复
JAMA Ophthalmol. 2015 Feb;133(2):230. doi: 10.1001/jamaophthalmol.2014.4505.
9
Reversible vision loss and outer retinal abnormalities after intravitreal ocriplasmin injection.玻璃体内注射奥克纤溶酶后出现可逆性视力丧失和视网膜外层异常。
Retin Cases Brief Rep. 2014 Fall;8(4):330-2. doi: 10.1097/ICB.0000000000000061.
10
Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin.玻璃体内注射奥克纤溶酶治疗有症状性玻璃体黄斑粘连眼的治疗效果及频域光学相干断层扫描结果
Am J Ophthalmol. 2015 Jan;159(1):20-30.e1. doi: 10.1016/j.ajo.2014.09.015. Epub 2014 Sep 16.

Acute ocriplasmin retinopathy.

作者信息

Johnson Mark W, Fahim Abigail T, Rao Rajesh C

机构信息

Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan.

出版信息

Retina. 2015 Jun;35(6):1055-8. doi: 10.1097/IAE.0000000000000667.

DOI:10.1097/IAE.0000000000000667
PMID:25996428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4457368/
Abstract
摘要